The utility of ⁶⁸Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Dasari A, Shen C, Halperin D et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 26(13), 2124–2130 (2017).
  Google Scholar
• 2 Perren A, Couvelard A, Scoazec J-Y et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 90(2), 162–166 (2017).
  Google Scholar
• 3 Jaïs P, Terris B, Ruszniewski P et al. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur. J. Clin. Invest. 27(8), 639–644 (1997).
  Medline CASGoogle Scholar
• 4 Rinke A, Müller H-H, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J. Clin. Oncol. 27(28), 4656–4663 (2009).
  Medline CASGoogle Scholar
• 5 Caplin ME, Pavel M, Ćwikła JB et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371(3), 224–233 (2014).
  MedlineGoogle Scholar
• 6 Wolin E, Jarzab B, Eriksson B et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des. Devel. Ther. 9, 5075 (2015).
  Medline CASGoogle Scholar
• 7 Sadowski SM, Neychev V, Millo C et al. Prospective study of ⁶⁸Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J. Clin. Oncol. 34(6), 588–596 (2016). •• A prospective study showing the impact of 68Ga-DOTATATE PET/CT of NET management.
  Medline CASGoogle Scholar
• 8 Graham MM, Gu X, Ginader T, Breheny P, Sunderland J. Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and meta-analysis. J. Nucl. Med. 58(9), 1452–1458 (2017). •• A comprehensive meta-analysis about the role of 68Ga-DOTATOC in neuroendocrine tumor (NET) detection.
  Medline CASGoogle Scholar
• 9 Pruthi A, Pankaj P, Verma R, Jain A, Belho ES, Mahajan H. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. J. Gastrointest. Oncol. 7(3), 449–461 (2016).
  MedlineGoogle Scholar
• 10 Strosberg J, El-Haddad G, Wolin E et al. Phase III trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376(2), 125–135 (2017).
  Medline CASGoogle Scholar
• 11 Krenning EP, Bakker WH, Breeman WA et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1(8632), 242–244 (1989).
  Medline CASGoogle Scholar
• 12 Sundin A, Arnold R, Baudin E et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology doi:10.1159/000471879 (2017) (Epub ahead of print). • Current ENTES guidelines for imaging modality selection in patients with NET.
  Google Scholar
• 13 Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract. Res. Clin. Gastroenterol. 26(6), 803–818 (2012).
  MedlineGoogle Scholar
• 14 Deppen SA, Liu E, Blume JD et al. Safety and efficacy of ⁶⁸Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J. Nucl. Med. 57(5), 708–714 (2016).
  Medline CASGoogle Scholar
• 15 Niederle B, Pape U-F, Costa F et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 103(2), 125–138 (2016).
  Medline CASGoogle Scholar
• 16 Deppen SA, Blume J, Bobbey AJ et al. 68Ga-DOTATATE compared with ¹¹¹In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J. Nucl. Med. 57(6), 872–878 (2016).
  Medline CASGoogle Scholar
• 17 Hofman MS, Lau WFE, Hicks RJ. Somatostatin receptor imaging with ⁶⁸Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35(2), 500–516 (2015). •• A comprehensive review on 68Ga-DOTATATE positron emission tomography (PET)/computed tomography for various medical indications including NETs.
  MedlineGoogle Scholar
• 18 Baumann T, Rottenburger C, Nicolas G, Wild D. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) – imaging and staging. Best Pract. Res. Clin. Endocrinol. Metab. 30(1), 45–57 (2016).
  MedlineGoogle Scholar
• 19 Kuyumcu S, Özkan ZG, Sanli Y et al. Physiological and tumoral uptake of (⁶⁸)Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann. Nucl. Med. 27(6), 538–545 (2013).
  Medline CASGoogle Scholar
• 20 Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q. J. Nucl. Med. Mol. Imaging 54(1), 61–67 (2010).
  Medline CASGoogle Scholar
• 21 Kroiss A, Putzer D, Decristoforo C et al. ⁶⁸Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur. J. Nucl. Med. Mol. Imaging 40(4), 514–523 (2013).
  Medline CASGoogle Scholar
• 22 Ayati N, Lee ST, Zakavi SR et al. Sandostatin LAR therapy differentially alters ⁶⁸Ga-DOTATATE uptake in normal tissues compared with primary tumors and metastatic lesions. J. Nucl. Med. doi:10.2967/jnumed.117.192203 (2017) (Epub ahead of print).
  MedlineGoogle Scholar
• 23 Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 40(11), 1770–1780 (2013).
  Medline CASGoogle Scholar
• 24 Kayani I, Bomanji JB, Groves A et al. Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112(11), 2447–2455 (2008).
  MedlineGoogle Scholar
• 25 Gabriel M, Decristoforo C, Kendler D et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 48(4), 508–518 (2007).
  Medline CASGoogle Scholar
• 26 Frilling A, Sotiropoulos GC, Radtke A et al. The impact of ⁶⁸Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann. Surg. 252(5), 850–856 (2010).
  MedlineGoogle Scholar
• 27 Schraml C, Schwenzer NF, Sperling O et al. Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging 13(1), 63–72 (2013).
  Medline CASGoogle Scholar
• 28 Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of ⁶⁸Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on ¹¹¹In-DTPA-octreotide scintigraphy. J. Nucl. Med. 51(6), 875–882 (2010).
  Medline CASGoogle Scholar
• 29 Naswa N, Sharma P, Kumar A et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. Am. J. Roentgenol. 197(5), 1221–1228 (2011).
  MedlineGoogle Scholar
• 30 Ambrosini V, Campana D, Nanni C et al. Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? Eur. J. Nucl. Med. Mol. Imaging 39(8), 1278–1283 (2012).
  Medline CASGoogle Scholar
• 31 Naswa N, Sharma P, Gupta SK et al. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using ⁶⁸Ga-DOTA-NOC PET-CT and ¹⁸F-FDG PET-CT. Clin. Nucl. Med. 39(1), e27–e34 (2014).
  MedlineGoogle Scholar
• 32 Venkitaraman B, Karunanithi S, Kumar A, Khilnani GC, Kumar R. Role of ⁶⁸Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur. J. Nucl. Med. Mol. Imaging 41(5), 856–864 (2014).
  Medline CASGoogle Scholar
• 33 Jindal T, Kumar A, Venkitaraman B, Dutta R, Kumar R. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids. Korean J. Intern. Med. 25(4), 386–391 (2010).
  MedlineGoogle Scholar
• 34 Kayani I, Conry BG, Groves AM et al. A comparison of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT in pulmonary neuroendocrine tumors. J. Nucl. Med. 50(12), 1927–1932 (2009).
  MedlineGoogle Scholar
• 35 Ambrosini V, Castellucci P, Rubello D et al. ⁶⁸Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl. Med. Commun. 30(4), 281–286 (2009).
  MedlineGoogle Scholar
• 36 Schreiter NF, Nogami M, Steffen I et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur. Radiol. 22(2), 458–467 (2012).
  MedlineGoogle Scholar
• 37 Haug A, Auernhammer CJ, Wängler B et al. Intraindividual comparison of ⁶⁸Ga-DOTA-TATE and ¹⁸F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 36(5), 765–770 (2009).
  Medline CASGoogle Scholar
• 38 Albanus DR, Apitzsch J, Erdem Z et al. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared with stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). Eur. J. Radiol. 84(10), 1866–1872 (2015).
  Medline CASGoogle Scholar
• 39 Putzer D, Gabriel M, Henninger B et al. Bone metastases in patients with neuroendocrine tumor: ⁶⁸Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J. Nucl. Med. 50(8), 1214–1221 (2009).
  MedlineGoogle Scholar
• 40 Ambrosini V, Nanni C, Zompatori M et al. ⁶⁸Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 37(4), 722–727 (2010).
  MedlineGoogle Scholar
• 41 Daniels CE, Lowe VJ, Aubry M-C, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 131(1), 255–260 (2007).
  MedlineGoogle Scholar
• 42 KRÜGER S, BUCK AK, BLUMSTEIN NM et al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J. Intern. Med. 260(6), 545–550 (2006).
  Medline CASGoogle Scholar
• 43 Luo G, Liu Z, Guo M et al. ¹⁸F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. Int. J. Oncol. 45(4), 1531–1536 (2014).
  Medline CASGoogle Scholar
• 44 Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom. Imaging 29(6), 696–702 (2004).
  Medline CASGoogle Scholar
• 45 Koopmans KP, de Vries EG, Kema IP et al. Staging of carcinoid tumours with ¹⁸F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 7(9), 728–734 (2006).
  Medline CASGoogle Scholar
• 46 d'Assignies G, Fina P, Bruno O et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology 268(2), 390–399 (2013).
  MedlineGoogle Scholar
• 47 Dromain C, de Baere T, Lumbroso J et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J. Clin. Oncol. 23(1), 70–78 (2005).
  MedlineGoogle Scholar
• 48 Caplin ME, Baudin E, Ferolla P et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann. Oncol. 26(8), 1604–1620 (2015).
  Medline CASGoogle Scholar
• 49 Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 55(4), 389–398 (2014).
  MedlineGoogle Scholar
• 50 Bardram Johnbeck C, Knigge U, Kjaer A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 10(14), 2259–2277 (2014).
  Google Scholar
• 51 Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42(1), 80–87 (2012).
  Medline CASGoogle Scholar
• 52 Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (⁶⁸)Ga-DOTA-NOC receptor PET/CT. Eur. J. Nucl. Med. Mol. Imaging 37(1), 67–77 (2010).
  Medline CASGoogle Scholar
• 53 Tirosh A, Stemmer SM, Solomonov E et al. Pasireotide for malignant insulinoma. Hormones 15(2), 271–276 (2016).
  MedlineGoogle Scholar
• 54 Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 30(5), 781–793 (2003).
  Medline CASGoogle Scholar
• 55 Nockel P, Babic B, Millo C et al. Localization of insulinoma Using ⁶⁸Ga-DOTATATE PET/CT Scan. J. Clin. Endocrinol. Metab. 102(1), 195–199 (2016).
  Google Scholar
• 56 Oberg K, Hellman P, Ferolla P, Papotti M, ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl. 7), vii120–vii123 (2012).
  MedlineGoogle Scholar
• 57 Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic factors in patients treated with ²²³Ra: the role of skeletal tumor burden on baseline ¹⁸F-fluoride PET/CT in predicting overall survival. J. Nucl. Med. 56(8), 1177–1184 (2015).
  Medline CASGoogle Scholar
• 58 Tirosh A, Papadakis GZ, Millo C et al. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total (⁶⁸)Ga-DOTATATE-avid tumor volume measurements. Eur. J. Endocrinol. 176(5), 575–582 (2017).
  Medline CASGoogle Scholar
• 59 Ruf J, Schiefer J, Furth C et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J. Nucl. Med. 52(5), 697–704 (2011).
  MedlineGoogle Scholar
• 60 Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V et al. Simultaneous ⁶⁸Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest. Radiol. 48(5), 273–279 (2013).
  Medline CASGoogle Scholar
• 61 Sawicki LM, Deuschl C, Beiderwellen K et al. Evaluation of (⁶⁸)Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with (⁶⁸)Ga-DOTATOC PET/CT. Eur. Radiol. 27(10), 4091–4099 (2017). •• A study reporting a potential role for 68Ga-DOTA based PET/MRI for NET detection.
  MedlineGoogle Scholar
• 62 Garcia-Carbonero R, Sorbye H, Baudin E et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103(2), 186–194 (2016).
  Medline CASGoogle Scholar
• 63 Ramage JK, De Herder WW, Delle Fave G et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology 103(2), 139–143 (2016).
  Medline CASGoogle Scholar
• 64 Falconi M, Eriksson B, Kaltsas G et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103(2), 153–171 (2016).
  Medline CASGoogle Scholar
• 65 Pape UF, Niederle B, Costa F et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 103(2), 144–152 (2016).
  Medline CASGoogle Scholar
• 66 Fave GD, O'Toole D, Sundin A et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 103(2), 119–124 (2016).
  MedlineGoogle Scholar
• 67 Pavel M, O'Toole D, Costa F et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2), 172–185 (2016).
  Medline CASGoogle Scholar
• 68 Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J. Med. Imaging Radiat. Oncol. 56(1), 40–47 (2012). • A prospective study showing the impact of 68Ga-DOTATATE PET/computed tomography of NET management.
  MedlineGoogle Scholar
• 69 Froeling V, Elgeti F, Maurer MH et al. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann. Nucl. Med. 26(9), 738–743 (2012).
  Medline CASGoogle Scholar
• 70 Sadowski SM, Millo C, Cottle-Delisle C et al. Results of ⁶⁸Gallium-DOTATATE PET/CT scanning in patients with multiple endocrine neoplasia type 1. J. Am. Coll. Surg. 221(2), 509–517 (2015).
  MedlineGoogle Scholar
• 71 Prasad V, Tiling N, Denecke T, Brenner W, Plöckinger U. Potential role of ⁶⁸Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel–Lindau disease. Eur. J. Nucl. Med. Mol. Imaging 43(11), 2014–2020 (2016).
  Medline CASGoogle Scholar
• 72 Hicks RJ, Kwekkeboom DJ, Krenning E et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology doi:10.1159/000475526 (2017) (Epub ahead of print).
  Google Scholar
• 73 Kratochwil C, Stefanova M, Mavriopoulou E et al. SUV of [⁶⁸Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol. Imaging Biol. 17(3), 313–318 (2015).
  Medline CASGoogle Scholar
• 74 Werner RA, Lapa C, Ilhan H et al. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget 8(4), 7039–7049 (2017).
  MedlineGoogle Scholar
• 75 Haug AR, Auernhammer CJ, Wangler B et al. ⁶⁸Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J. Nucl. Med. 51(9), 1349–1356 (2010). • The utility of 68Ga-DOTATATE in predicting response to peptide-receptor radionuclide therapy in patients with NET.
  Medline CASGoogle Scholar
• 76 Sharma P, Naswa N, Kc SS et al. Comparison of the prognostic values of ⁶⁸Ga-DOTANOC PET/CT and ¹⁸F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor. Eur. J. Nucl. Med. Mol. Imaging 41(12), 2194–2202 (2014).
  Medline CASGoogle Scholar
• 77 Campana D, Ambrosini V, Pezzilli R et al. Standardized uptake values of (⁶⁸)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J. Nucl. Med. 51(3), 353–359 (2010).
  MedlineGoogle Scholar
• 78 Ambrosini V, Campana D, Polverari G et al. Prognostic value of ⁶⁸Ga-DOTANOC PET/CT SUVmax in patients with neuroendocrine tumors of the pancreas. J. Nucl. Med. 56(12), 1843–1848 (2015).
  Medline CASGoogle Scholar
• 79 Tirosh A, Papadakis GZ, Millo C et al. High total 68Ga-DOTATATE-avid tumor volume (TV) is associated with low progression-free survival and high disease-specific mortality rate in patients with neuroendocrine tumors. Endocrine Abstracts 49, OC7.3 (2017).
  Google Scholar
• 80 Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer 12(4), 1083–1092 (2005).
  MedlineGoogle Scholar
• 81 Partelli S, Rinzivillo M, Maurizi A et al. The role of combined Ga-DOTANOC and (¹⁸)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. Neuroendocrinology 100(4), 293–299 (2014).
  Medline CASGoogle Scholar
• 82 Kayani I, Conry BG, Groves AM et al. A comparison of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT in pulmonary neuroendocrine tumors. J. Nucl. Med. 50(12), 1927–1932 (2009).
  MedlineGoogle Scholar
• 83 Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. ¹⁸F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 16(3), 978–985 (2010).
  Medline CASGoogle Scholar
• 84 Shi C, Gonzalez RS, Zhao Z et al. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. Am. J. Clin. Pathol. 143(3), 398–404 (2015).
  MedlineGoogle Scholar
• 85 Chan DL, Pavlakis N, Schembri GP et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics 7(5), 1149–1158 (2017).
  Medline CASGoogle Scholar